SLC5A2 and type 2 diabetes mellitus: In addition, SGLT2 inhibitors have the potential to improve cardiovascular risk profiles, including lower blood pressure and weight loss, as well as to reduce glycated hemoglobin levels in T2DM patients [4–7].